EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel dual-pathogen multi-epitope mRNA vaccine development for Brucella melitensis and Mycobacterium tuberculosis in silico approach

Yuejie Zhu, Juan Shi, Quan Wang, Yun Zhu, Min Li, Tingting Tian, Huidong Shi, Kaiyu Shang, Zhengwei Yin, Fengbo Zhang iD

PLOS ONE · 28.10.2024 · 19 (10) · e0309560

DOI: 10.1371/journal.pone.0309560 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 28.10.2024. Verfasst von Yuejie Zhu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Reproductive Assistance, Center for Reproductive Medicine, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjia…. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Brucella melitensis, Epitopes, T-Lymphocyte. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Youth Science and Technology Top Talent Program, Xinjiang Uygur Autonomous Region Science and Technology Support Project, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Brucellosis and Tuberculosis, both of which are contagious diseases, have presented significant challenges to global public health security in recent years. Delayed treatment can exacerbate the conditions, jeopardizing patient lives. Currently, no vaccine has been approved to prevent these two diseases simultaneously. In contrast to traditional vaccines, mRNA vaccines offer advantages such as high efficacy, rapid development, and low cost, and their applications are gradually expanding. This study aims to develop multi-epitope mRNA vaccines argeting Brucella melitensis and Mycobacterium tuberculosis H37Rv (L4 strain) utilizing immunoinformatics approaches. The proteins Omp25, Omp31, MPT70, and MPT83 from the specified bacteria were selected to identify the predominant T- and B-cell epitopes for immunological analysis. Following a comprehensive evaluation, a vaccine was developed using helper T lymphocyte epitopes, cytotoxic T lymphocyte epitopes, linear B-cell epitopes, and conformational B-cell epitopes. It has been demonstrated that multi-epitope mRNA vaccines exhibit increased antigenicity, non-allergenicity, solubility, and high stability. The findings from molecular docking and molecular dynamics simulation revealed a robust and enduring binding affinity between multi-epitope peptides mRNA vaccines and TLR4. Ultimately, Subsequently, following the optimization of the nucleotide sequence, the codon adaptation index was calculated to be 1.0, along with an average GC content of 54.01%. This indicates that the multi-epitope mRNA vaccines exhibit potential for efficient expression within the Escherichia coli(E . coli) host. Analysis through immune modeling indicates that following administration of the vaccine, there may be variation in immunecell populations associated with both innate and adaptive immune reactions. These types encompass helper T lymphocytes (HTL), cytotoxic T lymphocytes (CTL), regulatory T lymphocytes, natural killer cells, dendritic cells and various immune cell subsets. In summary, the results suggest that the newly created multi-epitope mRNA vaccine exhibits favorable attributes, offering novel insights and a conceptual foundation for potential progress in vaccine development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisBrucella melitensisEpitopes, T-LymphocyteHumansMolecular Docking SimulationEpitopes, B-LymphocyteMolecular Dynamics SimulationComputer SimulationVaccine DevelopmentmRNA VaccinesBrucellosisTuberculosisTuberculosis VaccinesRNA, Messenger

Substanzen

Epitopes, T-LymphocyteEpitopes, B-LymphocytemRNA VaccinesTuberculosis VaccinesRNA, Messenger

Autor:innen und Institutionen

  • Department of Reproductive Assistance, Center for Reproductive Medicine, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
  • The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
  • The Eighth Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
  • Xinjiang Uygur Autonomous Region Disease Prevention Control Center, Urumqi, Xinjiang, China.
  • Department of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
  • State Key Laboratory of Pathogenesis, Prevention, Treatment of Central Asian High Incidence Diseases, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.

ORCID-Profile: Fengbo Zhang

Förderung

  • Youth Science and Technology Top Talent Program
  • Xinjiang Uygur Autonomous Region Science and Technology Support Project
  • State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia Fund
  • Science and Technology Department of Xinjiang Uygur Autonomous Region, Outstanding Youth Project
  • National Natural Science Foundation of China and regional science foundation projects

Zitieren

APA

Zhu, Y., Shi, J., Wang, Q., Zhu, Y., Li, M., Tian, T., Shi, H., Shang, K., Yin, Z., & Zhang, F. (2024). Novel dual-pathogen multi-epitope mRNA vaccine development for Brucella melitensis and Mycobacterium tuberculosis in silico approach. PLOS ONE, 19(10), e0309560. https://doi.org/10.1371/journal.pone.0309560

Vancouver

Zhu Y, Shi J, Wang Q, Zhu Y, Li M, Tian T, et al. Novel dual-pathogen multi-epitope mRNA vaccine development for Brucella melitensis and Mycobacterium tuberculosis in silico approach. PLOS ONE. 2024;19(10):e0309560. doi:10.1371/journal.pone.0309560

BibTeX
@article{Zhu2024,
  author = {Zhu, Yuejie and Shi, Juan and Wang, Quan and Zhu, Yun and Li, Min and Tian, Tingting and Shi, Huidong and Shang, Kaiyu and Yin, Zhengwei and Zhang, Fengbo},
  title = {Novel dual-pathogen multi-epitope mRNA vaccine development for Brucella melitensis and Mycobacterium tuberculosis in silico approach},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {10},
  pages = {e0309560},
  doi = {10.1371/journal.pone.0309560}
}
Kostenlos starten →